Despite the existence of safe and effective FDA-approved medications for opioid use disorder (OUD), only a small percentage of individuals with OUD receive treatment and the rate of returning to opioid use after treatment is relatively high.…
Prevalence and Treatment of Opioid Use Disorder Among Primary Care Patients
Evidence-based treatment of opioid use disorder (OUD) includes medication treatment with methadone, buprenorphine, or naltrexone. However, the large number of people needing treatment for OUD currently outstrips treatment capacity, and improving access to OUD…
Depressive Symptoms and Cannabis Use in Study of N-Acetylcysteine for Cannabis Use Disorder
Approximately 12% of people who have used cannabis in the past year are estimated to have cannabis use disorder (CUD). Forty percent of people with a diagnosis of CUD also meet criteria for a mood disorder, with major depressive disorder (MDD) being the…
Barriers to Recruitment of HIV+ Individuals with OUD in the CHOICES Trial
Substance use disorders (SUD) are common in individuals with HIV, and untreated SUD is associated with increased HIV risk behaviors, decreased use of and/or adherence to antiretroviral therapy, decreased viral suppression, and greater HIV-related symptoms.…
Electronic Self-Administered Screening for Substance Use in Adult Primary Care Patients
Screening for substance use in primary care or general medical settings requires the use of a tool that identifies illicit and prescription opioid use as a component of a general screen for problem use of alcohol, tobacco…
Barriers to Screening for Substance Use in Rural Primary Care
Though addressing substance use is one of the top 10 priorities of Rural Healthy People 2020, a national initiative to identify and promote rural health priorities and effective programs, accessing treatment is particularly challenging in rural regions.…
Systematic Scoping Review of Black Participants in CTN Research Reveals Important Racial/Ethnic Differences and Untapped Opportunities
Black individuals experience a disproportionate burden of substance use-related disabilities and premature death, and Blacks with more severe substance use problems are less likely than Whites to receive treatment.
…
Mutual-Help Attendance Has Additive Benefit for Those Receiving Agonist Treatment for Prescription Opioid Dependence
The Prescription Opioid Addiction Treatment Study (POATS), carried out as part of the NIDA Clinical Trials…